The Olfactory Bulb Provides a Radioresistant Niche for Glioblastoma Cells.

Autor: Timme CR; Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland., Degorre-Kerbaul C; Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland., McAbee JH; Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland; Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom; Wake Forest University School of Medicine, Winston-Salem, North Carolina., Rath BH; Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland., Wu X; Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, Maryland., Camphausen K; Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland., Tofilon PJ; Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland. Electronic address: philip.tofilon@nih.gov.

Publikováno v: International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2020 May 01; Vol. 107 (1), pp. 194-201. Date of Electronic Publication: 2020 Jan 25.

Targeting PRMT5 enhances the radiosensitivity of tumor cells grown in vitro and in vivo.

Autor: Degorre, Charlotte¹ (AUTHOR), Lohard, Steven¹ (AUTHOR), Bobrek, Christina N.¹ (AUTHOR), Rawal, Komal N.¹ (AUTHOR), Kuhn, Skyler² (AUTHOR), Tofilon, Philip J.¹ (AUTHOR) philip.tofilon@nih.gov

Publikováno v: Scientific Reports. 7/27/2024, Vol. 14 Issue 1, p1-10. 10p.

Radiation Drives the Evolution of Orthotopic Xenografts Initiated from Glioblastoma Stem-like Cells.

Autor: McAbee JH; Radiation Oncology Branch, NCI, Bethesda, Maryland.; Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.; Wake Forest University School of Medicine, Winston-Salem, North Carolina., Rath BH; Radiation Oncology Branch, NCI, Bethesda, Maryland., Valdez K; Radiation Oncology Branch, NCI, Bethesda, Maryland., Young DL; Radiation Oncology Branch, NCI, Bethesda, Maryland., Wu X; Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland., Shankavaram UT; Radiation Oncology Branch, NCI, Bethesda, Maryland., Camphausen K; Radiation Oncology Branch, NCI, Bethesda, Maryland., Tofilon PJ; Radiation Oncology Branch, NCI, Bethesda, Maryland. philip.tofilon@nih.gov.

Publikováno v: Cancer research [Cancer Res] 2019 Dec 01; Vol. 79 (23), pp. 6032-6043. Date of Electronic Publication: 2019 Oct 15.

The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and as Orthotopic Xenografts.

Autor: Timme CR; Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland., Rath BH; Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland., O'Neill JW; Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland., Camphausen K; Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland., Tofilon PJ; Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland. tofilonp@mail.nih.gov.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2018 Jun; Vol. 17 (6), pp. 1207-1216. Date of Electronic Publication: 2018 Mar 16.

Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example.

Autor: Eke I; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. iris.eke@nih.gov., Makinde AY; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Aryankalayil MJ; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Sandfort V; Department of Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland., Palayoor ST; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Rath BH; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Liotta L; Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia., Pierobon M; Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia., Petricoin EF; Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia., Brown MF; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Stommel JM; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Ahmed MM; Radiation Research Program, National Cancer Institute, National Institutes of Health, Rockville, Maryland., Coleman CN; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.; Radiation Research Program, National Cancer Institute, National Institutes of Health, Rockville, Maryland.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2018 Feb; Vol. 17 (2), pp. 355-367. Date of Electronic Publication: 2017 Aug 11.